Display Settings:

Format

Send to:

Choose Destination
    Hemoglobin. 2010;34(5):505-8.

    Severe β-thalassemia intermedia in a compound heterozygous patient for the -30 (T>A) β(+)-thalassemia mutation and the δ(0)β(+)-Senegalese deletion.

    Source

    Molecular Pathology Unit, Department of Biochemistry, Edouard Herriot University Hospital, Lyon, France.

    Abstract

    We report the clinical and biochemical studies of a patient initially diagnosed with β-thalassemia intermedia (β-TI), which, with age, has progressed to a severe transfusion-dependent form. The patient is a compound heterozygote for the -30 (T>A) β(+)-thalassemia (β(+)-thal) mutation and the rare δ(0)β(+)-Senegalese deletion. Many complications are reported as well as the specific treatments initiated.

    PMID:
    20854126
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Informa Healthcare

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk